This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
I'm LongbridgeAI, I can summarize articles.Wall Street analysts downgraded several stocks on Tuesday. HSBC downgraded Banco Santander Brasil to Hold with a $6.2 price target. Rosenblatt downgraded Ribbon Communications to Neutral, cutting the target to $2.2. Citizens downgraded Cellectis to Market Perform. Barclays downgraded Scholar Rock to Equal-Weight but raised its target to $58. Raymond James downgraded Ascendis Pharma to Outperform, maintaining a $287 target.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- HSBC analyst Carlos Gomez-Lopez downgraded Banco Santander Brasil SA ADR (NYSE:BSBR) from Buy to Hold and cut the price target from $7.2 to $6.2. Banco Santander closed at $5.95 on Monday. See how other analysts view this stock.
- Rosenblatt analyst Mike Genovese downgraded Ribbon Communications Inc (NASDAQ:RBBN) from Buy to Neutral and cut the price target from $3.5 to $2.2. Ribbon Communications shares closed at $2.00 on Monday. See how other analysts view this stock.
- Citizens analyst Silvan Turkcan downgraded Cellectis SA (NASDAQ:CLLS) from Market Outperform to Market Perform. Cellectis closed at $1.83 on Monday. See how other analysts view this stock.
- Barclays analyst Etzer Darout downgraded Scholar Rock Holding Corp (NASDAQ:SRRK) from Overweight to Equal-Weight and raised the price target from $55 to $58. Scholar Rock shares closed at $51.85 on Monday. See how other analysts view this stock.
- Raymond James analyst Martin Auster downgraded Ascendis Pharma A/S (NASDAQ:ASND) from Strong Buy to Outperform and maintained the price target of $287. Ascendis Pharma closed at $264.92 on Monday. See how other analysts view this stock.
Considering buying CLLS stock? Here’s what analysts think:
Photo via Shutterstock